Education
About Us
Working with TipRanks
Follow Us
Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
RESEARCH TOOLSreports
CYP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.14 - AU$0.29
Previous CloseN/A
Volume63.41K
Average Volume (3M)229.22K
Market Cap
$48.68M
Enterprise ValueAU$33.73M
Total Cash (Recent Filing)$10.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding237,454,380
10 Day Avg. Volume254,146
30 Day Avg. Volume229,222
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue19.39
Enterprise Value/Gross Profit21.09
Enterprise Value/Ebitda-3.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was AU$0.14 and its highest was AU$0.28 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is $48.68M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Sep 01, 2025 which is in 3 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 27, 2025. The company reported -AU$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.02.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 237,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -AU$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.043%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
Cynata Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYP Sentiment 95%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.89%
12-Months-Change
Fundamentals
Return on Equity
-75.39%
Trailing 12-Months
Asset Growth
-13.26%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchymal stem cells (MSCs) at scale. This platform enables the production of therapeutic stem cells without the limitation of donor availability, supporting the treatment of various diseases and medical conditions. Cynata's core products target applications in regenerative medicine, encompassing indications such as cardiovascular disease, respiratory ailments, and graft-versus-host disease (GvHD).
Technical Analysis
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
Ownership Overview
0.87% Insiders
―
Mutual Funds
― Other Institutional Investors
99.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---